Dashboard
Manage Tickers

VTRSViatris Inc

Nasdaq viatris.com


$ 11.01 $ -0.05 (-0.45 %)    

Thursday, 16-May-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 451.64 $ -0.92 (-0.2 %)
DIA $ 399.14 $ -0.07 (-0.02 %)
SPY $ 528.49 $ -1.09 (-0.21 %)
TLT $ 92.06 $ -0.09 (-0.1 %)
GLD $ 220.06 $ -0.86 (-0.39 %)
$ 11.02
$ 11.01
$ 0.00 x 0
$ 0.00 x 0
$ 10.97 - $ 11.24
$ 8.54 - $ 13.48
9,715,938
na
13.12B
$ 0.89
nm
TBD
na
na ($ 0.04)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 02-28-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-08-2023 03-31-2023 10-Q
6 02-27-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 02-28-2022 12-31-2021 10-K
11 11-08-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
14 03-01-2021 12-31-2020 10-K
15 11-10-2020 09-27-2020 10-Q
16 08-12-2020 06-28-2020 10-Q
17 05-12-2020 03-29-2020 10-Q
18 05-07-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

weak-sales-from-lipitor-norvasc-hurt-viatris-q1-earnings-lowers-annual-forecast
Weak Sales From Lipitor, Norvasc Hurt Viat...
05/09/2024 18:23:13

Viatris reports Q1 EPS in line with consensus at $0.67, with sales slightly missing expectations at $3.66 billion. Strong growt...

stocks-rebound-as-rising-jobless-claims-sustain-rate-cut-hopes-dollar-falls-gold-rallies-whats-driving-markets-thursday
Stocks Rebound As Rising Jobless Claims Su...
05/09/2024 16:42:34

Wall Street is seeing a day of gains as all major indices traded in the green around noon in New York, driven by a surprising u...

viatris-expects-2024-adjusted-eps-of-266-281-versus-prior-guidance-of-270-285-and-consensus-of-274
Viatris Expects 2024 Adjusted EPS Of $2.66...
05/09/2024 11:06:22

viatris-expects-2024-revenues-of-1498b-1548b-versus-consensus-of-1519b-and-prior-guidance-of-1525b-1575b
Viatris Expects 2024 Revenues Of $14.98B-$...
05/09/2024 11:05:24

viatris-q1-2024-gaap-eps-067-inline-sales-3663b-miss-3691b-estimate
Viatris Q1 2024 GAAP EPS $0.67, Inline, Sa...
05/09/2024 11:01:57

Viatris (NASDAQ:VTRS) reported quarterly earnings of $0.67 per share which met the analyst consensus estimate. This is a 12.99 ...

viatris-launched-unmind-as-part-of-its-global-wellbeing-program-elevate
Viatris Launched Unmind As Part Of Its Glo...
05/01/2024 11:14:46

viatris-reports-launch-of-first-bioequivalent-generic-version-of-copaxone-20-mgml-once-daily-in-canada
Viatris Reports Launch Of First Bioequival...
04/15/2024 11:01:49

theramex-says-currently-considering-cmas-decision-in-particular-whether-and-how-best-to-address-competition-concerns-regarding-deal-with-viatris--co-remains-committed-to-offering-women-choice-to-make-empowered-decisions-about-hrt-at-competitive-prices-for-nhs-phase-1-of-cmas-decision-to-have-no-impact-on-cos-ability-to-supply-existing-hrt-products-in-uk
Theramex Says Currently Considering CMA's ...
04/05/2024 16:53:09

- Reuters

Core News & Articles
Ocuphire Announces the US Commercial Launc...
04/01/2024 11:17:13

 Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the ...

viatris-announced-the-us-commercial-launch-of-ryzumvi-phentolamine-ophthalmic-solution-075-for-pharmacologically-induced-mydriasis-ryzumvi-is-now-the-only-us-commercially-available-fda-approved-eye-drop-to-reverse-dilation
Viatris Announced The U.S. Commercial Laun...
04/01/2024 11:00:44

piper-sandler-reiterates-neutral-on-viatris-raises-price-target-to-13
Piper Sandler Reiterates Neutral on Viatri...
03/28/2024 16:22:26

Piper Sandler analyst David Amsellem reiterates Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $11 to...

looking-into-viatriss-recent-short-interest
Looking Into Viatris's Recent Short Interest
03/15/2024 13:00:14

earlier-on-monday-viatris-mapi-pharma-received-an-fda-complete-response-letter-regarding-the-new-drug-application-for-ga-depot-40mg-the-companies-are-reviewing-the-content-of-the-crl-and-will-be-determining-the-appropriate-next-steps
Earlier On Monday, Viatris' Mapi Pharma Re...
03/11/2024 14:55:54

stocks-fall-ahead-of-feds-inflation-data-unitedhealth-sinks-bitcoin-tops-61000-whats-driving-markets-wednesday
Stocks Fall Ahead Of Fed's Inflation Data,...
02/28/2024 19:08:12

Stocks dipped modestly following a report indicating a marginal downward revision in the U.S. economic growth rate for the last...

viatris-expects-fiscal-year-2024-adjusted-eps-of-270-285-versus-consensus-of-281
Viatris Expects Fiscal Year 2024 Adjusted ...
02/28/2024 11:36:04

viatris-expects-fiscal-year-2024-revenues-of-1525b-1575b-versus-consensus-of-1519b
Viatris Expects Fiscal Year 2024 Revenues ...
02/28/2024 11:35:15

viatris-q4-adjusted-eps-062-misses-065-estimate-sales-383b-miss-387b-estimate
Viatris Q4 Adjusted EPS $0.62 Misses $0.65...
02/28/2024 11:33:43

Viatris (NASDAQ:VTRS) reported quarterly earnings of $0.62 per share which missed the analyst consensus estimate of $0.65 by 4....

earnings-scheduled-for-february-28-2024
Earnings Scheduled For February 28, 2024
02/28/2024 11:24:02

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenu...

viatris-and-idorsia-forge-global-partnership-for-breakthrough-heart-attack-treatments
Viatris And Idorsia Forge Global Partnersh...
02/28/2024 10:20:01

Viatris and Idorsia collaborate on groundbreaking heart attack treatments, leveraging innovative therapies for acute conditions.

Core News & Articles
Viatris And Idorsia Enter Into Significant...
02/28/2024 08:12:18

Expands Viatris' Portfolio of Innovative Assets by Immediately Adding Two Phase 3 Assets, Selatogrel and Cenerimod, Both ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION